64th American Society of Hematology Annual Meeting and Exposition to Feature New Outcomes Research from Analysis Group

Dr. DerSarkissian’s expertise includes epidemiologic methodology and applications of modern methods to observational health data. She has a wide range of experience in pharmacoepidemiology, biostatistics, and health economics and outcomes research, including studies on causal methods. Dr. DerSarkissian has conducted cost-effectiveness and comparative effectiveness studies; examined treatment patterns, drug adherence, health care resource utilization and costs, and clinical outcomes; assessed direct medical and indirect productivity costs of a disease burden; assessed patient-reported quality of life and the humanistic burden of a disease; and worked on Food and Drug Administration (FDA) post-marketing authorization safety studies. She has used data from electronic medical records, clinical trials, commercial insurance claims, patient surveys, and medical chart review studies in disease areas that include obesity; HIV/AIDS; cardiovascular diseases; schizophrenia; autoimmune, neurologic, and rare hereditary disorders; and many types of cancer. Dr. DerSarkissian has provided regulatory and strategic consulting on drug and medical device registration and real-world evidence generation for regulatory submissions, such as new drug applications (NDAs) and supplemental new drug applications (sNDAs). She has also conducted real-world evidence studies to contextualize the results of clinical trials in support of NDA and sNDA submissions. She has presented her research at conferences on epidemiology and health services, and published articles in a number of peer-reviewed journals. Dr. DerSarkissian is an adjunct assistant professor in the epidemiology department at the UCLA Fielding School of Public Health.

Read Maral's profile 

Dr. Duh, Chief Epidemiologist at Analysis Group, specializes in real-world evidence (RWE) generation for product registration, post-approval safety studies, and health economics and outcomes research (HEOR) of pharmaceuticals, vaccines, and regenerative biotherapeutics. She has led multiple projects for new molecular entity approvals and product label expansion applications to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), as well as health technology assessment (HTA) research for submissions to national payers such as the Centers for Medicare and Medicaid Services (CMS) in the US and the UK’s National Institute for Health and Care Excellence (NICE). Her extensive research has appeared in over 250 peer-reviewed publications.

Her work also extends to pharmaceutical liability litigation and securities fraud litigation related to adverse drug events that allegedly led to product recalls, market withdrawals, black box warnings, and FDA limited access programs.

Dr. Duh is also an adjunct in the biostatistics department at the Harvard T.H. Chan School of Public Health. She served as a chairperson of drug safety and epidemiology for the Drug Information Association (DIA) and was an adjunct assistant professor of pharmacoeconomics and pharmacoepidemiology at Massachusetts College of Pharmacy and Allied Health Sciences. Dr. Duh was appointed to an expert panel convened by the Foundation for the National Institutes of Health’s (FNIH’s) Observational Medical Outcomes Partnership (OMOP). She has served as a peer reviewer for several journals, including PharmacoEconomics, the American Journal of Health-System Pharmacy, Chest, Pharmacoepidemiology and Drug Safety, the American Journal of Kidney Diseases, and Therapeutics and Clinical Risk Management. Dr. Duh is also an elected member of the American Society of Hematology and a member of the American Society of Clinical Oncology, the International Society of Pharmacoepidemiology, and the International Society of Pharmacoeconomics and Outcomes Research (ISPOR).

View Dr. Duh's selected publications on the Harvard Catalyst website

Mr. Émond specializes in biostatistics and economics within the field of health economics and outcomes research (HEOR). He has conducted a range of investigations into epidemiology, quality of life, patient-reported outcomes, cost of illness, resource utilization patterns, treatment patterns, cost-effectiveness, and treatment outcomes in the areas of oncology, hepatitis, chronic inflammatory diseases, epilepsy, diabetes mellitus, schizophrenia, cardiovascular diseases, infectious diseases, and hematology. Mr. Émond also has extensive experience performing retrospective database analyses, retrospective medical chart review studies, systematic literature reviews, cost models, and clinical trial data analyses. He has presented his research at numerous international conferences, including meetings of the American Psychiatric Association (APA), International AIDS Society (IAS), American Society of Clinical Oncology (ASCO), and American Society of Hematology (ASH), and published articles in several peer-reviewed journals. Mr. Émond has served as a peer reviewer for The American Journal of Managed Care, CNS Drugs, and the Journal of Managed Care & Specialty Pharmacy, and is a member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

Mr. Germain specializes in health economics and outcomes research (HEOR). He has extensive experience in retrospective database/claims analyses; clinical efficacy, safety profile, treatment patterns, and medication compliance studies; and biostatistics, epidemiology, and health outcomes research with advanced statistical methods, such as survival analysis, general estimating equations, and nonparametric testing. Mr. Germain has conducted research on a broad range of diseases and conditions, including asthma, chronic obstructive pulmonary disease, bipolar disorder, major depressive disorder, atrial fibrillation, venous thromboembolism, cancer, schizophrenia, and hepatitis C. His research has been presented at international conferences including those of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), the Academy of Managed Care Pharmacy (AMCP), the American Heart Association (AHA), and the American Association for the Study of Liver Diseases (AASLD). Mr. Germain’s research and analyses have been published in peer-reviewed journals including The Oncologist, the Journal of Asthma, the Journal of Chronic Obstructive Pulmonary Disease, Clinical Therapeutics, and the Journal of Medical Economics.

Ms. Guérin is an economist who specializes in the application of statistics and econometrics to health economics and outcomes research (HEOR) and epidemiology. Her areas of expertise include retrospective database analyses such as medical claims, electronic health records, and clinical trial data; economic modeling, such as cost-effectiveness and budget impact models; and design of chart review studies, surveys, and other prospective studies. She has participated in the development of large clinical data registries and in the design of real-world evidence (RWE) studies to support regulatory submissions. Ms. Guérin has broad research and analytical experience in areas such as comparative effectiveness and cost effectiveness, development of prediction algorithms, assessment of disease prevalence and incidence, evaluation of burden of illness, productivity loss, treatment patterns, analysis of patient-reported outcomes (PROs), safety/tolerability analyses, discrete choice experiments, and patient experience studies. She has also supported many pharmaceutical companies in the development of HEOR planning and RWE generation plans. Ms. Guérin has conducted health care research across many therapeutic areas, including oncology, hematology, dermatology, gastroenterology, rheumatology, neurology, psychiatry, endocrinology, cardiology and circulatory diseases, and respiratory diseases. She publishes frequently and is the coauthor of over 100 research papers published in numerous peer-reviewed journals and presented at a variety of scientific conferences.

Dr. Huynh specializes in epidemiologic methodologies and health economics and outcomes research (HEOR), and has extensive experience collecting real-world clinical data through medical charts using center-based and physician panel-based approaches. She has conducted comparative effectiveness and cost-effectiveness research on various diseases, including aplastic anemia, asthma, chronic lymphocytic leukemia, chronic myelogenous leukemia, colorectal cancer, dry eye disease, dysfunctional uterine bleeding, epilepsy, hemophilia, hepatitis B, HIV, inflammatory bowel disease, lung cancer, metachromatic leukodystrophy, myelofibrosis, multiple sclerosis, neuroendocrine tumors, non-Hodgkin’s lymphoma, primary open-angle glaucoma, renal cell carcinoma, sickle cell disease, and thromboembolism. Dr. Huynh has experience designing and developing case report forms, coordinating with clinical centers for data collection, developing discrete choice experiment surveys, designing quality of life and humanistic burden surveys, leading qualitative interviews, performing mixed methods research, performing systematic reviews, analyzing longitudinal cohort studies, and developing discrete event simulation models and economic evaluations. She has been involved in conducting several real-world evidence studies to examine the natural history of disease progression in order to contextualize the results of single-arm trials in support of regulatory new drug application (NDA) or supplemental NDA submissions.

Mr. Laliberté specializes in biostatistics and the economics of health outcomes research. He investigates multiple facets of health research, including safety, cost of illness, resource utilization, adherence to therapies, cost effectiveness, and treatment outcomes. Mr. Laliberté’s varied research has examined numerous forms of mental illnesses, respiratory diseases, cancer, cardiovascular diseases, and rare diseases. His expertise includes the retrospective database analysis of claims and electronic medical records, as well as clinical trial data analyses. He has implemented innovative data solutions such as Komodo Health, Mass General Brigham’s Research Patient Data Registry, and IQVIA to address clients’ research questions. Mr. Laliberté’s research has been presented at conferences of the American Heart Association (AHA) and the American Society of Clinical Oncology (ASCO), among others. He has published over 100 papers in medical journals, including CHEST, the American Journal of Hematology, and the Journal of Affective Disorders.

Mr. Lefebvre specializes in the application of biostatistics and economics of health outcomes research. He has conducted and directed numerous studies in pharmacoeconomics, epidemiology, and health outcomes research in a variety of therapeutic areas such as anemia, asthma, cardiovascular diseases, chronic obstructive pulmonary disease, diabetes, genetic syndrome, hematology, hypertension, infectious diseases, myelodysplastic syndromes, neurological disorders, obesity, oncology, renal diseases, respiratory diseases, and women’s health. His recent work in the health care sector includes numerous clinical trials and medical claims data analyses to investigate resource utilization patterns, patient-reported quality of life, clinical effectiveness, direct medical and indirect productivity costs of a disease burden, and cost-effectiveness associated with the use of pharmaceuticals.

His extensive research is reflected in over 100 peer-reviewed publications in prominent clinical and health economics journals, such as Neurology, Journal of Allergy and Clinical Immunology, Journal of the American Society of Nephrology, Cancer, Hypertension, American Journal of Managed Care, Journal of Managed Care Pharmacy, Value in Health, and PharmacoEconomics. His scientific research has also resulted in numerous presentations at health care conferences as well as presentations to the FDA and CMS, and has included several high-profile studies publicized in the media, including a recent article on the economic burden of vasomotor symptoms in post-menopausal women cited in The Wall Street Journal blog Pharmalot.

Mr. Lefebvre has also served as a peer reviewer for several journals, including CHEST, Annals of Oncology, Clinical Journal of the American Society of Nephrology, Allergy & Asthma Proceedings, Journal of Managed Care Pharmacy, American Journal of Managed Care, Value in Health, and PharmacoEconomics. He is also a member of the International Society of Pharmacoepidemiology and the International Society of Pharmacoeconomics and Outcomes Research. Prior to joining Analysis Group, Mr. Lefebvre was an economist with the Québec Ministry of Finance.

Read Patrick's profile

Dr. Sajeev’s expertise is in the application of statistical and epidemiologic methods to the design and analysis of clinical and real-world studies of health care data. He also has a wide range of experience in health economics and outcomes research (HEOR), including comparative effectiveness studies; indirect treatment comparisons; systematic and targeted literature reviews; and chart review, survey, and patient preference studies. Dr. Sajeev’s research has covered a variety of therapeutic areas, including neuromuscular disorders, rare genetic diseases, hematology, neurology, and psychiatry. In his work on Duchenne muscular dystrophy, he has collaborated with academic experts, biotech and pharmaceutical companies, and other stakeholders on research to inform drug development and clinical trial design. Dr. Sajeev’s research has been used in submissions to clinical regulators and health care payers, presented at numerous conferences, and published in peer-reviewed journals such as Neurology, Circulation, Epidemiology, The American Journal of Psychiatry, and Movement Disorders.

Dr. Signorovitch advises life sciences companies on data analytics for business critical research and decision making. He has broad experience leading the strategic development and implementation of analytics across the product life cycle, from early-phase clinical studies to market access and real-world evidence generation. Dr. Signorovitch’s practice areas span trial design, multi-stakeholder collaborations, natural history studies, regulatory interactions, health economic modeling, global reimbursement submissions, policy evaluation, real-world evidence development, individualized medicine, predictive analytics, and due diligence for acquisitions. He has particular expertise in developing and applying new methodologies to address health care research challenges, and in designing analytics platforms to enhance collaborative research and decision making. Dr. Signorovitch’s work has been used to inform clinical regulators and health care payers in US and global markets, published in peer-reviewed journals, and presented at clinical and economic research conferences. Prior to joining Analysis Group, Dr. Signorovitch was a research fellow at the Harvard-MIT Division of Health Sciences and Technology.

Dr. Song is an epidemiologist with expertise in biostatistics and clinical medicine, which he uses to address a wide array of analytical questions in health care. He has broad experience designing and implementing advanced and innovative real-world data analytic and economic modeling solutions for pharmaceutical clients. Dr. Song conducts research to evaluate and compare the clinical, economic, and humanistic impacts of diseases and treatments across a variety of therapeutic areas. He is experienced in disease areas such as oncology, hematology, infectious diseases and vaccines, dermatology, rheumatology, cardiology, and endocrinology. Dr. Song has provided cross-indication consulting for multiple blockbuster pharmaceutical products, as well as novel pipeline agents. In his work, he uses data from clinical trials, administrative claims, medical chart reviews, surveys, qualitative interviews, and medical literature. His research has covered many different study types, including disease epidemiology, burden of illness, disease treatment and management patterns, comparative effectiveness research, individualized medicine, systematic literature reviews, indirect treatment comparisons, economic modeling such as cost-effectiveness analyses and budget impact analyses, analyses of patient-reported outcomes, and preference research such as discrete choice experiments. Dr. Song’s work has been published in peer-reviewed journals and presented at international conferences on medical and health care research.

Dr. Zanardo specializes in formalizing economic and statistical models designed to evaluate health outcomes, measure online advertisements’ effectiveness, and assess the merits of antitrust claims in high-tech and pharmaceutical markets. In his health economics work, Dr. Zanardo has modeled differences in health care resource utilization and costs between patient cohorts, designed surveys to collect patient outcomes from electronic medical records, and applied machine-learning algorithms to derive predictive models. In his litigation work, he has supported academic affiliates in projects that have involved measuring consumers’ willingness to pay for consumer goods, modeling the market for online display advertisements on social networks, and investigating the impact of Amazon reviews on online and offline sales. Dr. Zanardo has experience analyzing a wide variety of datasets, including medical and pharmacy claims datasets, Nielsen consumer goods scanner data from leading US retailers, Slice online sales data, proprietary internal profit and loss reports, and drug formulary placement.

Dr. Zhou is a health economist with extensive experience in health economics and outcomes research. Her expertise includes economic evaluation, health technology assessment, and comparative effectiveness research using clinical and real-world evidence. Dr. Zhou has developed evidence submissions – including systematic literature reviews, indirect treatment comparisons, and cost-effectiveness analyses – for health technology appraisals in the UK, EU, and Canada. She also has extensive experience supporting clients through the ICER review process in the US. Dr. Zhou’s additional research has involved evaluating Medicare’s Oncology Care Model (OCM) program; assessing disease burden of illness and treatment patterns; and developing pharmaceutical pricing strategies based on early stage modeling. Her experience encompasses a wide range of therapeutic areas, including oncology and hematology, rare bleeding disorders, genetic diseases, autoimmune diseases, mental health disorders, cardiovascular diseases, and infectious diseases. Dr. Zhou’s work has been published in many peer-reviewed journals and featured at numerous conferences.